Protein kinase C isozymes as therapeutic targets for treatment of human cancers.
Fields
Alan P
AP
Mayo Clinic Comprehensive Cancer Center, Department of Cancer Biology, Jacksonville, FL, USA. fields.alan@mayo.edu
Murray
Nicole R
NR
D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics; D003110:Colonic Neoplasms; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D007527:Isoenzymes / Q000502:physiology / Q000627:therapeutic use; D020014:K562 Cells; D008175:Lung Neoplasms / Q000235:genetics; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D009857:Oncogenes / Q000502:physiology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000502:physiology / Q000627:therapeutic use*; D051381:Rats; D015398:Signal Transduction / Q000502:physiology; D000099293:Protein Kinase C-lambda
D007211:Indoles; D007527:Isoenzymes; D011493:Protein Kinase C; D000099293:Protein Kinase C-lambda; C504878:enzastaurin